CODA Biotherapeutics
South San Francisco
About CODA Biotherapeutics
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allows for exquisite, dose-dependent control of the neurons to generate the therapeutic effect.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $62.7M
- Last round: Debt Financing (Dec 2021)
- Website: codabiotherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/coda-biotherapeutics-23004 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.